Introduction
In Chapter 4, we stated that a cohort effect is the effect occurring from the risk factors of the disease which causes a change in the disease occurrence in the population. In this chapter, we will discuss what factors contribute to cohort effects, the importance of cohort effects in understanding the disease pattern in the population, and how to evaluate a cohort effect for disease rates. Before we go into detail, let us first consider the importance of the cohort effect in understanding the disease pattern in the population from the data presented in Figure 6 .1a and Figure 6 .1b. Figure 6 .1a provided a complete picture regarding these cancers, then UK public health workers would have cause to celebrate for their achievements in preventing and controlling these deadly diseases during the past decades. This is, however, not the complete picture; cautious scientists conducted the birth cohort analysis of the disease rates. There are two types of birth cohort analyses for disease rates: one is a univariate analysis (including presenting the disease rates by age cohort curves, period cohort curves, and birth cohort-age curves -see detailed description later in the chapter), and the other is statistical modelling (such as age-period cohort modelling -see Chapter 7). Figure 6 .1b presents the results from one univariate cohort analysis for these cancers, using birth cohort-age curves. In contrast to the optimistic trend shown in Figure 6 .1a, the results in Figure 6 .1b actually suggest an alarmingly worrying trend; these cancers have actually been increasing among the majority of the age groups (aged 35-69) of the population in recent birth cohorts. The stable overall mortality rates observed in this population in Figure 6 .1a are due to the scale of reduction in disease rates in the three oldest age groups (70-74, 75-79, and 80-84) matched almost exactly by the scale of increase from other younger age groups, and thus masked this increasing trend in recent birth cohorts. If this increasing trend in recent birth cohorts were to continue without intervention, the overall secular trend of these cancers would soon show an increase, as the disease rates from the oldest age groups are replaced by that from the younger age groups in the population in the coming decades.
From this example, we have learned that it is often not enough to merely examine the overall secular trend for disease rates, and it is in fact necessary to explore the cohort effect even for diseases which apparently show no clear secular trend pattern, as was the case in Figure 6 .1a. An epidemic of cancers of the lip, oral cavity, and pharynx in British males could be anticipated in the coming years if nothing is done about the risk factors of the diseases in the population. Fortunately, scientists did not solely rely on the results from overall secular trend analysis presented in Figure  6 .1a.
Although a univariate cohort analysis of disease rate cannot guarantee whether the apparent cohort pattern observed in Figure 6 .1b indeed comes from a cohort effect, the results from the cohort analysis, however, do help scientists look for answers; if the increase proves to be true from a cohort effect, then measures can be taken to stop the epidemic from realization.
Definition Cohort effect
In descriptive epidemiology, the change in disease rate due to varying degrees of exposure to risk factors by different generations is referred to as a generational effect or a cohort effect. A cohort effect reflects a real change in disease rate, since it comes from the changes in the risk factors of the disease.
A cohort in descriptive epidemiology is generally referred to as a birth cohort, which includes all persons born within a specified period of time. Birth cohort is of particular interest in descriptive epidemiology because it is believed that the disease risk of a generation is established at a very early stage in the lives of its members. People born within a defined period of time would carry, throughout their lives, a relatively higher or lower risk for certain diseases compared to other birth cohorts. Therefore, by examining the disease rates by birth cohorts, factors uniquely associated with the birth cohorts can be identified.
It should be noted however, that a cohort effect is by no means limited only to events that occurred around the time of birth; any risk factor for a particular disease could produce a birth cohort effect if it differentiates itself from generation to generation in terms of both quality and quantity of exposure, even if this exposure did not occur around the time of birth. This is particularly true for exposures which have a long-term induction and latency period, such as cancer. For example, when lung cancer incidence and mortality rates are examined, the rates show a strong cohort effect for tobacco smoking, even though smoking as a habit was not picked up around the time of birth. In this instance, a cohort simply acts as a generational identifier.
Birth cohort pattern
We have concluded that when a risk factor for a disease has a tendency to affect generations differently, the risk factor will produce an apparent birth cohort pattern for the incidence rates of the disease. This birth cohort pattern is created by a real change in the risk of the disease. We should also keep in mind that the term 'cohort pattern', is not equal to cohort effect, since not all apparent birth cohort patterns for disease rates arise from a cohort effect. For example, Figure 6 .2 presents the age-specific incidence rates of non-Hodgkin's lymphoma for Connecticut males. Figure 6 .2a presents the disease rates for six generations born between 1885 and 1935 by age cohort curves that connect the age-specific disease rates for each birth cohort. In Figure 6 .2b, the disease rates are presented for the same data by period cohort curves that connect the calendar-year-specific rate for each birth cohort. In Figure 6 .2c, the disease rates are presented for the same data by birth cohort-age curves that connect the disease rates for the same age group but for those born in different years. All three figures show a birth cohort pattern which suggests an increase in disease rates in succeeding birth cohorts. We cannot, however, be sure this apparent birth cohort pattern is the result of a birth cohort effect, based on the univariate analysis performed, since a period effect (an artificial change in disease rate) could also have caused a birth cohort pattern for disease rate. Slow but progressive improvements in diagnosis, registration, and ascertainment may also produce a birth cohort pattern when disease rates are examined, and therefore, simulate a cohort effect.
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Introduction
Two major tasks in epidemiological research are: studying the distribution of the diseases and investigating the determinants of diseases in the population, and the ultimate goal of epidemiological research is to prevent and control diseases. Thus, the concept of disease is essential in epidemiology for achieving the goal of epidemiologic research.
It is vital to have a valid disease definition for any type of epidemiological study, whether the goal of a study is to identify risk factors for a disease, or to identify prognostic factors that determine the outcomes of a disease (also see Figure 9 .1). A valid disease definition is important because it ensures that the cases recruited for the study represent a homogeneous disease entity. In many situations, 'disease' in the context of epidemiological research may be more accurately referred to as the 'outcome of interest', because the 'disease' could be early symptoms or signs, or reversible or irreversible biological changes or markers at cellular, genetic, or epigenetic levels, as shown in Figure 9 .1.
For example, both epidemiological and laboratory studies have shown that multiple genes/ pathways are involved in the progression from normal oral mucosa to hyperplasia, dysplasia, in situ oral cancer, and eventually invasive oral cancer (Figure 9 .2). The progression results from alterations in genes/pathways which control cellular signalling, cell cycle, apoptosis, genomic stability, cytoskeleton, and angiogenesis [1] . Some of these changes are reversible, while others may not be. For example, some, but not all, cases of oral epithelial dysplasia progress into oral cancer. In fact, some actually regress over time [1] . Many studies have been conducted in an effort to discover the potential value of molecular markers with respect to identification of dysplasia and their ability to predict the malignant potential of pre-cancers of the oral cavity, with the eventual goal of developing diagnostic biomarkers [1] . It is expected that, as our understanding of the disease process improves and as discovery of specific early disease biomarkers advances, more and more epidemiological studies will and should focus on early events in the disease process, rather than on clinical diagnosis of the disease endpoint.
There are situations in which 'diseases' or 'abnormal' conditions or 'positive' results in epidemiological studies (as well as in clinical settings) are defined simply by an empirical, arbitrary cut-off point embedded in a continuum of values, as shown in Figure 9 .3. Using heart rate as an example, 60-100 heart beats per minute (bpm) are considered the normal range for a resting adult ( Figure  9 .3a). However, if the resting heart rate goes below 60 bpm or above 100 bpm, the rate would be considered abnormal, with the former situation labelled as 'bradycardia' and the latter referred to as 'tachycardia'. It is common knowledge that heart rate differs from person to person and also varies over time, based on individual differences, as well as other factors such as the individual's physiological response to the environment, the effect of strenuous physical activity and emotional stress, and how well the individual is physically conditioned. A heart rate below 50 bpm is not uncommon for healthy people who engage in regular physical activity. Extremely well-trained and conditioned athletes, such as cyclists who are Tour de France competitors, can have resting heart rates in the 30s or even mid-20s. It has been suggested that resting bradycardia in an athlete should not be considered abnormal if the individual has no symptoms associated with it. Similarly, other physiological cut-off points can also be quite arbitrary in their definition -such as low blood pressure or hypertension; low birthweight or macrosomia; or a high serum level of prostate-specific antigen (PSA). For example, when measuring blood pressure, for individuals aged 18-45 years, a systolic pressure of 120 mmHg and a diastolic pressure of 80 mmHg (120/80 mmHg) is considered normal (Figure 9 .3b), while having a measurement above 140/90 mmHg would be considered hypertensive, and having a measurement below 90/60 mmHg would be deemed hypotensive. We know, however, that individuals who engage in regular and vigorous physical exercise can have blood pressures much lower than the so called 'normal' values.
Similarly, the average weight of a newborn at full term is about 3,400 grams; newborns weighing between 2,500 and 4,000 grams are considered normal (Figure 9 .3c). Newborns weighing less than 2,500 grams are considered to have low birthweight, while those with a birthweight above 4,000 grams would be referred to as macrosomic. From a methodological perspective, it is difficult to see how different a birthweight of 3,998 grams and a birthweight of 4,002 grams can be; small increments in measurement can force membership in a category created by an arbitrary definition. Another example of this process can be found in the definitions of hypoglycaemia and hyperglycaemia (Figure 9 .3d). During a fasting blood glucose test, a blood glucose level below 70 mg/dL is considered hypoglycaemic; ranges between 70 and 99 mg/dL are considered 'normal', and values which lie between 100 and 125 mg/dL are defined as pre-diabetic, while levels consistently above 126 mg/dl are considered hyperglycaemic which suggesting a diabetic condition. Again, the choice of cut-off points can be rather arbitrary.
In prostate cancer screening, serum level of PSA has been used as a biomarker. Concentrations of ≤4 ng/mL, 4-10 ng/mL, 10-20 ng/mL, and 20-35 ng/mL are considered normal, slightly elevated, moderately elevated, and highly elevated, respectively (Figure 9 .4). The interpretation of PSA values is challenging, however, as many men with prostate cancer have been found to have normal PSA levels (i.e. false-negative results), while most men with elevated PSA levels do not have prostate cancer (i.e. false-positive results).
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Introduction
Modern molecular methods are now rapidly becoming an integral part of many epidemiological studies. While laboratory methods to measure molecular and genetic factors are described in Chapter 15, this chapter deals with the integration of molecular methods into cancer epidemiology studies to measure exposure, early evidence of malignant transformation, and individual susceptibility. Such epidemiological studies are subject to problems of design and analysis similar to those encountered in traditional cancer epidemiological investigations, which are discussed in other chapters of this textbook.
The use of biological approaches to measure variables of interest in epidemiological studies is not new. In the areas of infectious and cardiovascular diseases, research that would nowadays be considered to be molecular epidemiology has been conducted for decades. As an example, Figure  24 .1 shows the results linking elevated serum cholesterol levels to the risk of ischaemic heart disease in the Framingham prospective study [1] . During the last decade, however, the use of biomarkers in cancer epidemiology has greatly increased. Several reasons may explain this trend. The identification of new carcinogens, characterized by complex exposure circumstances and weak effects, has become increasingly difficult with traditional epidemiological approaches. In parallel, increasing knowledge of mechanisms of carcinogenesis led to the proposal of models involving genetic and epigenetic events, as well as cellular and histological alterations. These models, which need to be tested in human studies, represent an adequate theoretical framework for molecular epidemiological research.
Furthermore, developments in molecular biology and genetics, such as the use of robots and the increasing throughput of automatic analytical equipments, allow the large-scale application of assays that would otherwise be very resource-intensive.
It is useful to consider molecular epidemiology investigations within the framework of epidemiological studies in general. Aetiological research in epidemiology aims at identifying determinants of disease and quantifying their role, while taking into account sources of random and systematic error (bias and confounding), as well as factors which modify the effect of the determinant(s) of interest. To a large extent, molecular epidemiological studies fit into the same framework: they represent epidemiological studies, in which risk factors, outcomes, confounders, or effect modifiers are measured with biomarkers. Similarly, the same arguments should be applied to the design, analysis and interpretation of molecular and more traditional epidemiological studies.
In practice, there is a continuum from the development of biomarkers to be applied in human studies, to their characterization in early field studies, and to their application in full-scale epidemiological investigations [2] . However, these logical steps are often bypassed, with promising but yet un-validated biomarkers being applied in human studies. While this pattern reflects the vivacity of a young discipline, a more cautious approach is needed in order to avoid misuse of research resources.
In the context of epidemiological studies, a biomarker has been defined as a substance, structure, or process that (1) can be measured in the human body or its products, and (2) may influence the incidence or outcome of disease in human populations [3] . It is important to bear in mind the distinction between marker, assay, and measurement. While the marker is the variable to be measured, the assay is the test used to measure the marker, and the measurement is an individual value of the marker. A distinction has been made between markers of exposure, intermediate events, disease, and susceptibility (Figure 24 .2; Table 24 .1). This distinction, however, is somewhat arbitrary. For example, chromosomal aberrations have been used for decades to monitor exposure to environmental carcinogens. From this point of view, they can be classified as biomarkers of exposure. However, growing evidence points towards a role of chromosomal aberrations for prediction of cancer risk, irrespective of exposure [18] . In this respect, they can be seen as intermediate biomarkers. Furthermore, it is important to notice that any scheme, such as that represented in Figure 24 .2 reflects our current understanding of a complex biological phenomenon such as carcinogenesis, and our ability to measure events that are considered relevant to it. In other words, the steps in the carcinogenic process depicted in Figure 24 .2 represent 'boxes' where we allocate available biomarkers: in fact, more emphasis is given in the scheme to the early steps (internal dose, biologically effective dose, etc) than to the later steps, simply because of the larger availability of markers -and their simpler interpretation -to measure the former as compared to the latter events.
PRIMARY PREVENTION AND CLINICAL INTERVENTIONS
In fact, the increase in the understanding of the late steps in carcinogenesis, and the development of relevant and valid biomarkers, represent the main challenge to molecular cancer epidemiology.
Exposure biomarkers
In many instances, epidemiologic research is hampered by misclassification of exposure ascertained, for example, by means of questionnaires, interviews, or job histories. The rationale for using biomarkers is to measure the biologically relevant exposure more precisely. In some instances, there is an obvious improvement in using an exposure biomarker. Aflatoxin provides a good example in which exposure biomarkers represent a step forward in the identification of the human cancer hazard. The fungus Aspergillus flavus is a common contaminant of foodstuffs, in particular cereals and nuts. Exposure is common in West Africa and East Asia. Depending on storage conditions, A. flavus may produce a toxin called aflatoxin, with strong hepatotoxic and carcinogenic properties in animal models. It is difficult for study subjects to know whether the food they consume is contaminated by aflatoxin. Studies on the carcinogenic effect of aflatoxin are therefore limited by the difficulty of determining exposure status at the individual level, although ecological analyses indicated a higher incidence of hepatocellular carcinoma in contaminated areas than in neighbouring areas with less frequent contamination.
The identification of serum and urine biomarkers of aflatoxin exposure -namely urinary metabolites of aflatoxin itself and of its adducts formed with DNA -paved the way for important developments. Table 24 .2 reports an increased risk of hepatocellular carcinoma in the first study using exposure biomarkers in subjects with samples collected and stored prospectively. Individuals with any urinary marker of exposure had a 2.4-fold increased risk of liver cancer relative to individuals without markers; the relative risk was as high as 4.9 among individuals positive for the urinary adduct degradation product AFB 1 -N 7 guanine [9] . These results, which have been replicated in other populations, provide strong evidence of a causal association between aflatoxin and liver cancer in humans.
Principles of Screening
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General considerations
Screening for diseases is a relatively old practice in medicine. Screening programmes started after World War II, with nationwide programmes for early detection of tuberculosis through x-ray of the chest or cutaneous tests with tuberculin.
Few methods are suitable for screening in the general population. Screening is more commonly encountered among patients for timely diagnosis of relapse, detection of complication, and side effects of treatment. These screening activities in patients allow timely management of these conditions, which may prevent fatal outcomes.
In this chapter, we will mainly talk about screening of cancer in the general population, because a great deal of what we know on early detection and screening comes from the oncology domain, and because general public screening is always challenging. Most of what is said in this chapter also applies to non-cancerous chronic diseases. A huge literature exists for early detection and screening for disease, and readers can find further details on each topic in textbooks and other published literature.
We will first present the traditional theoretical aspects underlying early detection and screening activities, as they were set some 20 years ago. As the chapter progresses, we will briefly outline the considerable changes in our understanding of cancer occurrence that have taken place since then, and the consequences that these new observations may have on early detection and screening.
What are early detection and screening?
Early detection is the attempt to detect a disease in asymptomatic subjects at a stage when it can be cured, and before it naturally evolves into a further stage when it cannot be cured.
Screening is the systematic offering of early detection to the general public, to a specific group of the population or to patients with a specific disease profile. For instance, screening may be performed in subjects whose hereditary background puts them at higher risk to develop a disease. Such screening may prove inefficient in subjects without such a hereditary background. Screening may also be specific to patients with specific disease such as, for instance, early detection of head and neck cancer relapse or of colorectal cancer in patients with chronic colitis.
When subjects test positive at early detection or screening for a disease, they will always be referred to further clinical, laboratory, or surgical investigations (i.e., the work-up procedures) that will confirm or rule out the presence of the disease in that subject.
What is the goal of early detection and screening?
The essential goal of early detection and screening for a disease is to decrease the mortality associated with that disease. Figure 33 .1 sketches the classic model of key events in the development of cancer. The classical view is that cancer is preceded by precursor lesions that may evolve into a small invasive cancer which is not yet symptomatic or clinically detectable, and then further progress in a bigger tumour that triggers symptoms. Sometimes, the tumour is not yet symptomatic, but is detected by a doctor (e.g., during a routine medical exam) or by a relative (a classic example is that of the skin melanoma on the back or shoulders detected by the spouse). The next step is the discovery of regional spread of the cancer, because the cancer has invaded neighbouring organs, or of metastasis to distant organs. At these advanced stages, there is generally no cure, although there are notable exceptions, e.g., testis cancer is curable even when already metastasized.
The natural history of cancer and of other chronic diseases
Figures 33.2a and 33.2b illustrate the reasoning that supports screening for breast cancer: It has been known since long that the bigger the cancer at diagnosis, and the greater the number of axillary lymph nodes involved with metastases, the poorer the prognosis. Also, tumour size is a strong predictor of the presence of metastases in axillary lymph nodes. Hence, the goal of breast screening is to detect cancer when the tumours are less than 20 mm in size, which should lead to lowering the probability of having lymph nodes invaded by metastases, and dying from the cancer. It should be noted that the relationship between cancer size and survival, as depicted in Figures  33.2a and 33 .2b, is true on average. In reality, this relationship is a probabilistic one, that is, the probability to survive for a certain time after cancer diagnosis decreases with tumour size. This means that, in a number of patients, a small but aggressive cancer may already have metastasized, even when screen-detected. Conversely, a large cancer may just have grown locally without having metastasized.
In coronary heart disease or atheromatosis of large arteries like the aorta or the carotids, disease progression patterns have been well documented for several decades, and early detection of subjects with significant but still asymptomatic atheromatosis (precursor lesion) is relevant, since modern treatments are able to stop the extension or even induce regression of the atheromatosis plaques.
